Literature DB >> 18363127

Disulfiram neuropathy: two cases of distal axonopathy.

Massimiliano Filosto1, Marta Tentorio, Laura Broglio, Serena Buzio, Clara Lazzarini, Maria Pia Pasolini, Maria Sofia Cotelli, Mauro Scarpelli, Michelangelo Mancuso, Anna Choub, Alessandro Padovani.   

Abstract

BACKGROUND: Disulfiram may cause a peripheral neuropathy that is considered dose- and duration-of-exposure-related. Axonal degeneration has been described as a pathological hallmark of disulfiram toxicity, but experiments have reported a primary toxic effect of the molecule on Schwann cells and myelin. CASE REPORTS: Case 1: At the end of two months of treatment with disulfiram 250 mg/day, a 31-year-old woman complained of weakness in distal segments of the lower limbs associated with burning dysesthesias, numbness and pain in the soles of the feet and the legs below the knees; bilateral walking steppage, reduction in foot strength, absence of ankle jerk and knee tendon reflexes, and tactile stocking pin-pick and vibratory sensory impairment in the lower limbs below the knee. Disulfiram was discontinued and she recovered partially over three months. Case 2: After one month of treatment with disulfiram 1600 mg/day, a 27-year-old man reported walking impairment, distal lower limb weakness and paresthesias. He had unsteady gait with bilateral steppage and foot drop, absence of ankle jerks and overall sensation impairment below the knee. Disulfiram was discontinued and nine months later there was almost complete recovery of motor deficits, only minor motor weakness in distal leg muscles, and no dysesthesia, sensation deficits or areflexia. In both of them clinical and neurophysiological patterns were indicative of a distal axonopathy. DISCUSSION The mechanisms by which disulfiram cause injury in human nerves are unclear, though may involve carbon disulfide. The discrepancy between experimental and clinical observations is still unexplained.
CONCLUSION: We report two cases of disulfiram axonal toxicity and the partial response following discontinuation of the drug.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18363127     DOI: 10.1080/15563650701636390

Source DB:  PubMed          Journal:  Clin Toxicol (Phila)        ISSN: 1556-3650            Impact factor:   4.467


  6 in total

Review 1.  Alcohol use disorders and current pharmacological therapies: the role of GABA(A) receptors.

Authors:  Jing Liang; Richard W Olsen
Journal:  Acta Pharmacol Sin       Date:  2014-08       Impact factor: 6.150

Review 2.  Targeting aldehyde dehydrogenase 2: new therapeutic opportunities.

Authors:  Che-Hong Chen; Julio Cesar Batista Ferreira; Eric R Gross; Daria Mochly-Rosen
Journal:  Physiol Rev       Date:  2014-01       Impact factor: 37.312

Review 3.  A Comparative Review of Chemotherapy-Induced Peripheral Neuropathy in In Vivo and In Vitro Models.

Authors:  Sandy Eldridge; Liang Guo; John Hamre
Journal:  Toxicol Pathol       Date:  2019-07-22       Impact factor: 1.902

Review 4.  Repositioned Drugs for COVID-19-the Impact on Multiple Organs.

Authors:  Sean T Foster; Kayla G Chan; Matthew J Cacace; Shay L Ladd; Christina Chan; Caleb T Sandum; Paul T Wright; Brett Volmert; Weiyang Yang; Aitor Aguirre; Wen Li; Neil T Wright
Journal:  SN Compr Clin Med       Date:  2021-04-21

5.  Disulfiram neuropathy: two case reports.

Authors:  Anh Thu Tran; Richard A Rison; Said R Beydoun
Journal:  J Med Case Rep       Date:  2016-03-31

6.  Cell cycle specific radiosensitisation by the disulfiram and copper complex.

Authors:  Mathias Tesson; Giorgio Anselmi; Caitlin Bell; Robert Mairs
Journal:  Oncotarget       Date:  2017-07-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.